ArticleFrontiers in oncology2026
Sphingolipid metabolic enzyme GLA expression in gliomas: prognostic implications and therapeutic potential.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are the most common primary brain tumors and show marked molecular heterogeneity and variable clinical outcomes, highlighting the need for reliable prognostic biomarkers. Methods: We analyzed TCGA and CGGA datasets to identify prognosis-related genes in glioma and performed single-cell analysis and functional validation in glioma cell lines. Results: Ten prognosis-related genes were identified, among which GLA showed the strongest association with survival. Elevated GLA expression was significantly associated with higher WHO grade, therapy resistance, and worse prognosis. Time-dependent ROC analysis showed favorable predictive performance for 1-, 3-, and 5-year survival. Single-cell RNA sequencing revealed preferential GLA expression in tumor-associated astrocytes and grade-dependent upregulation. GLA expression was associated with sphingolipid metabolism, hypoxia-related pathways, and ERAD-related pathways, including EDEM2 expression. In glioma cell lines, GLA knockdown suppressed cell viability and downregulated EDEM2. Cross-database analyses further supported the diagnostic and prognostic relevance of GLA across cohorts. Conclusion: GLA may serve as a prognostic biomarker in glioma and is associated with metabolic and ERAD-related alterations, providing a potential direction for further mechanistic and therapeutic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.